期刊文献+

蛋白激酶C及其抑制物在肺癌中的活性表达及临床意义 被引量:2

Expression and clinical significances of protein kinase C and its inhibitors in lung cancer
下载PDF
导出
摘要 目的 对肺癌及相应的肺癌旁组织标本中蛋白激酶C(PKC)及其抑制物 (PKCI)的活性表达规律进行对照研究。方法 收集 2 6例肺癌及癌旁组织标本 ,通过检测同位素放射来测定标本胞浆和胞膜中PKC的比活性和PKCI对PKC活性抑制百分数。结果  2 6例肺癌组织细胞胞浆中PKC比活性显著高于癌旁组织 (P <0 .0 1) ;而非小细胞癌胸膜中PCK比活性明显低于癌旁组织 (P <0 .0 5 ) ,小细胞癌胞膜中PKC比活性与癌旁组织无明显差异 (P <0 ,0 5 )。另外 ,2 6例肺癌组织胞浆中PKCI的抑制活性明显低于癌旁组织 (P <0 .0 5 ) ,而胞膜中PKCI的抑制活性则与癌旁组织无显著差异 (P >0 .0 5 )。结论 肺癌组织中PKC被激活而活性增高 ,同时PKCI表达降低说明其对PKC的调控能力下降 ,以上表明PKC和PKCI可能在肺癌的发生及发展中起重要作用。 Objective To compare the active expression of PKC and PKCI in lung cancer with its paracancer tissue sample.Methods 26 lung cancer and paracancer tissue samples were collected and the specific activity in cell plasma and membrane and inhibition percentage of PKCI to PKC were detected by radio-activity of isotope.Results Specific activity of PKC in cytoplasma of 26 lung cancer tissues was obviously higher than that of paracancer tissue(P<0.01);while specific activity of PKC in cell membrane of non-small cell cancer was obviously lower than that of paracancer tissue (P<0.05).There was no obvious difference in specific activity of PKC between cell membrane of small cell cancer and paracancer tissue.In addition,the inhibiting activity of PKCI in cytoplasma of 26 lung cancer was obviously lower than that of paracancer tissue (P<0.05),but there was no significant difference of that in cell membrane (P>0.05).Conclusion In lung cancer,PKC is activated to higher activity with decreased expression of PKCI,which suggests decreased control ability of PKC.It is suggests that PKC and PKCI may play an important role in the pathogenesis and progression of lung cancer.
出处 《中国肿瘤临床与康复》 2002年第1期28-30,共3页 Chinese Journal of Clinical Oncology and Rehabilitation
关键词 蛋白激酶C 蛋白激酶C抑制物 肺癌 PCKI PKC lung cancer
  • 相关文献

参考文献6

二级参考文献8

共引文献30

同被引文献21

  • 1宋兴福,黄骥,王燕燕.肺癌组织中PKC-α蛋白的表达与肺癌临床病理特征的关系[J].肿瘤防治研究,2005,32(8):490-492. 被引量:8
  • 2宋兴福,黄骥,王燕燕.肺鳞癌/腺癌细胞浆和细胞膜PKC-α蛋白的表达及作用[J].中华实验外科杂志,2005,22(10):1233-1234. 被引量:7
  • 3Ohta,Inoue H,Cotticelli MG,et al.The FHIT gene,spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t (3;8) breakpoint,is abnormal in digestive tract cancers[J].Cell,1996,84(4):587-597.
  • 4Sozzi G,Veronese ML,Negrini M,et al.The FHIT gene 3p14.2 is abnormal in lung cancer[J].Cell,1996,85(1):17-26.
  • 5Cheng S,Gao Y,Dong X,et al.Molecular and cytogenetic alterations in early stage of carcinogenesis of human lung[J].Cancer Lett,2001,162(Suppl):S5-S10.
  • 6Tomizawa Y,Nakajima T,Kohno T,et al.Clinicopathological significance of FHIT protein in expression in stageⅠnonsmall cell lung carcinoma[J].Cancer Res,1998,58(23):5478-5483.
  • 7Zanesi N,Pekarsky Y,Croce CM.A mouse model of the fragile gene FHIT:From carcinogenesis to gene therapy and cancer prevention[J].Murat Res,2005,591(1-2):103-109.
  • 8Sharkey NA,Leach KL,Blumerg PM.Competitive inhibition by diacylglycerol of specific phorol ester binding[J].Proc Natl Acad Sci USA,1984,81(2):607-610.
  • 9Pearson JD,DeWald DB,Mathews WR,et al.Amino acid sequence and characterization of a protein inhibitor of protein kinase C[J].J Biol Chem,1990,265(8):4583-4591.
  • 10Brzoska PM,Chen H,Zhu Y,et al.The product of the ataxiatelangiectasia group D complementing gene,ATDC,interacts with a protein kinase C substrate and inhibitor[J].Proc Natl Acad Sci USA,1995,92(17):7824-7828.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部